Use of phyllanthus constituents for treating or preventing infections caused by hepatit

Abstract

The invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role. Furthermore, the invention relates to the use of one or more Phyllanthus component(s) or substances or mixture of substances obtained therefrom for the production of a pharmaceutical composition for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role. Furthermore, the invention relates to the use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the inhibition of the amplification of a hepatitis B virus which is resistant to nucleoside analogues. Moreover, the invention relates to methods for the prevention or treatment of infectious diseases in a mammal caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are administered to the mammal. Furthermore, the invention relates to methods for the inhibition of the amplification of a hepatitis B virus resistant to nucleoside analogues, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are contacted with the viruses. In a preferred embodiment of the invention, the nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.

1 . Use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role.  
     
     
         2 . Use of one or more Phyllanthus component(s) or substances obtained therefrom or mixture of substances for the production of a pharmaceutical composition for the prevention or treatment of infectious diseases caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role.  
     
     
         3 . Use according to  claim 1 , wherein the infectious disease is yellow fever, cirrhosis and hepatocellular carcinoma.  
     
     
         4 . Use of one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom for the inhibition of amplification of the hepatitis B virus which is resistant to nucleoside analogues.  
     
     
         5 . Use according to  claim 4 , wherein the inhibition takes place ex vivo or in vitro.  
     
     
         6 . Use according to  claim 1 , wherein the one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are derived from  Phyllanthus amarus, Phyllanthus niruri, Phyllanthus emblica, Phyllanthus urinaria, Phyllanthus acidus, Phyllanthus acuminatus  and  Phyllanthus reticulatus  or from several of these Phyllanthus species.  
     
     
         7 . Use according to  claim 1 , wherein the hepatitis B virus which is resistant to nucleoside analogues exhibits one or more mutations in the reverse transcriptase.  
     
     
         8 . Use according to  claim 7 , wherein this one or more mutation(s) comprise a substitution of an isoleucine by a methionine at position 552 or a position corresponding thereto.  
     
     
         9 . Use according to  claim 1 , wherein the prevention or the treatment comprises the inhibition of one or more viral enzymes.  
     
     
         10 . Use according to  claim 9 , wherein the inhibition comprises the inhibition of the processing of one or more viral enzymes.  
     
     
         11 . Use according to  claim 9 , wherein an enzyme is the reverse transcriptase.  
     
     
         12 . Use according to  claim 11 , wherein the reverse transcriptase exhibits a substitution of an isoleucine by a methionine at position 552 or a position corresponding thereto.  
     
     
         13 . Use according to  claim 1 , wherein the nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.  
     
     
         14 . Use according to  claim 1 , wherein the Phyllanthus constitutes comprise the herb drug, leaves, bark, blossom, seek, fruits, stalks, branches, stem, root and wood.  
     
     
         15 . Use according to  claim 1 , wherein the substances or mixture of substances are selected from the group consisting of alkaloids, tanning agents, lignanes, sesquiterpenes, triterpenes and cyanogenic glycosides.  
     
     
         16 . Use according to  claim 15 , wherein aqueous non-polar, branched or linear chain hydrocarbons with n-hexane are used during the extraction of the substance or the mixture of substances.  
     
     
         17 . Use according to  claim 16 , wherein the hydrocarbons have a C5- to C10-framework.  
     
     
         18 . Use according to  claim 15 , wherein alcohols and/or a mixture thereof are used during the extraction of the substance or the mixture of substances.  
     
     
         19 . Use according to  claim 18 , wherein the alcohols used are short-chain primary C1 to C4-alcohols and/or mixtures thereof.  
     
     
         20 . Use according to  claim 19 , wherein the alcohols used are methanol and/or ethanol.  
     
     
         21 . Use according to  claim 1 , wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are used in combination with other active agents.  
     
     
         22 . Use according to  claim 21 , wherein the other active agents are selected from the group consisting of interferon α, interferon β, interferon γ and ribavirin.  
     
     
         23 . Use according to  claim 1 , wherein the application takes place in the form of an infusion solution, an injection solution, a tablet, an ointment, a healing pack, a granular powder, a food additive or in the form of clysters.  
     
     
         24 . Use according to  claim 1 , wherein the application takes place orally, topically or parenterally.  
     
     
         25 . Method for the prevention or treatment of infectious diseases in a mammal caused by a hepatitis B virus which is resistant to nucleoside analogues or in the development or progression of which a hepatitis B virus resistant to nucleoside analogues plays a role, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are administered to the mammal.  
     
     
         26 . Method according to  claim 25 , wherein the mammal in a human.  
     
     
         27 . Method for the inhibition of the amplification of a hepatitis B virus which is resistant to nucleoside analogues, wherein one or more Phyllanthus component(s) or substances or mixtures of substances obtained therefrom are contacted with the viruses.  
     
     
         28 . Method according to  claim 27 , wherein the inhibition takes place ex vivo or in vitro.  
     
     
         29 . Method according to  claim 25 , wherein the nucleoside analogues are selected from the group consisting of Lamivudine and Famciclovir.